Qdata® Thyroid Eye Disease Provides Real-World Evidence Analytics to Help Improve Understanding of Rare Condition

Author:

Heather Moss, MD, PhD, Verana Health Medical Advisor

Real-world data on more than 250,000 de-identified patients can support life sciences companies with this clinically-identified patient cohort using key variables, including severity and clinical activity score.

Thyroid Eye Disease (TED) is diagnosed in roughly 1 million Americans, each year, with women being more than five times more likely to develop the disease than men. The condition occurs in association with autoimmune disease of the thyroid gland in the neck. It causes inflammation and enlargement of the muscles and fatty tissue behind the eyes in the eye sockets. This can then lead to dry or watery eyes, pain in the eye socket, disfiguration of the face due to bulging and swollen eyes, loss of vision and a variety of other issues. 

Treatment of TED is important to improve comfort, vision, and facial appearance. Until the launch of insulin-like growth factor 1 receptor (IGF-1r) blocking therapies, there was no targeted treatment option for TED. Patient care was mainly symptom-focused, until the symptoms subsided and surgery was performed to improve facial appearance and vision.   

To help advance TED research and expedite therapy development, Verana Health has launched Qdata® Thyroid Eye Disease, a real-world dataset consisting of more than 250,000 de-identified patients.

To help advance TED research and expedite therapy development, Verana Health has launched Qdata® Thyroid Eye Disease, a real-world dataset consisting of more than 250,000 de-identified patients. This meticulously curated dataset is made possible through Verana Health’s exclusive partnership with the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight). Our team of expert physicians and data scientists utilize IRIS Registry data, as well as secure and advanced artificial intelligence (e.g., machine learning and natural language processing) to extract TED diagnoses from clinical notes within electronic health records. 

Additional key variables will soon be added to the module, including the designation of TED severity (e.g., mild, moderate-to-severe, and sight-threatening) and Clinical Activity Score (CAS), which is obtained by documenting the presence or absence of certain symptoms (e.g., spontaneous pain) and signs (e.g., lid swelling, conjunctival redness, chemosis) of TED. These key variables will enable a level of analysis and understanding of this rare and unique condition that’s not available elsewhere. Such depth and insight is beneficial in helping life sciences companies accelerate therapy development, monitor real-world treatment patterns and outcomes, and inform site selection and patient identification for clinical trials.

Currently, there’s a need for research and innovative treatment approaches for TED, and real-world evidence – generated from curated, quality RWD – can help achieve breakthroughs in disease management and therapeutic efficacy for this population, which can be challenging to identify.

The launch of Qdata TED comes on the heels of Verana Health’s announcement of the development of Qdata Dry Eye Disease, which is the largest dataset of its kind that will include outcomes and clinical information on more than 10 million de-identified patients with dry eye disease and related ocular conditions. These datasets reinforce Verana Health’s commitment to further enhance ophthalmology research capabilities to improve the quality of care and quality of life for patients diagnosed with rare diseases.

To view details on our available Ophthalmology Qdata modules, click here.

Verana Health Logo

Let's Accelerate Research Together

To learn more about Verana Health, please fill out the information below and our team will follow up with you as soon as possible.